PDCD1 and metastatic melanoma: The anti-PD-1 monoclonal antibodies (mAbs) have been approved in monotherapy and combination therapy for treatment of metastatic melanoma, proving impressive clinical benefit [3–6] and long-term survival for up to 5 years [7, 8].